decibel therapeutics

Decibel Therapeutics Appoints New Chief Medical Officer and COO

BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced the appointment of Dr. Peter Weber as the company’s new Chief Medical Officer, as well as the promotion of Paula Cobb to Chief Operating Officer. Dr. Weber, an otolaryngologist at Boston University Medical Center specializing in otology/neurotology, brings experience as a clinician, a scientist and a hearing…

Read More
decibel therapeutics

Pharmaceutical Treatments for Hearing Loss, a Brief Q&A with Michael Su, Ph.D., CSO of Decibel Therapeutics

Hearing loss is a critical public health issue that carries a significant social and economic cost. Decibel Therapeutics, a biotechnology startup based in Boston, is pursuing a comprehensive approach to developing precision medications for hearing and balance. We talked with Decibel’s chief scientific officer, Michael Su, Ph.D., about that work. Su and his colleagues will…

Read More
frequency fx 322 fundraising

Frequency Therapeutics Completes $42 Million Series B Financing

WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced earlier this month that it has closed $42 million in Series B financing. The latest funding round for the company, which is seeking to create a new class of drugs based on small molecule stimulation of dormant stem cells within the body, brings the total capital raised…

Read More
sound pharmaceuticals

Sound Pharmaceuticals Advances Phase 2 Clinical Trial in Cystic Fibrosis Patients to Prevent Hearing Loss

SEATTLE, WASHINGTON AND CHARLESTON, SOUTH CAROLINA — Sound Pharmaceuticals, a Seattle-based biotech firm, announced that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial. This novel interventional study with the company’s oral drug, SPI-1005, is aimed to prevent and treat ototoxicity in patients with Cystic Fibrosis undergoing intravenous (IV) tobramycin for the…

Read More
decibel partnership cocoon

Decibel Therapeutics and Cocoon Biotech Announce Research Collaboration

BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced a research collaboration with Cocoon Biotech to apply Cocoon’s proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders. According to the announcement, the companies will jointly conduct research into drug formulations optimized for transtympanic delivery to the ear, and Decibel will…

Read More
spiral therapeutics hearing loss drug investment

Spiral Therapuetics Receives $3.7M Investment to Advance Treatment of Hearing Loss and Inner Ear Disorders

SAN FRANCISCO, CALIFORNIA — According to a news report out this week, early-stage pharmaceutical company Spiral Therapeutics has received a $3.7 million investment towards the development of treatments for hearing loss and other inner ear related disorders. The Series A funding round was led by Camden Partners Nexus, a biomedical-focused venture fund, and Savoir Capital.  Spiral Therapeutics’ initial…

Read More
hearing loss drug clinical trial

Frequency Therapeutics Completes Enrollment in Safety Trial for Hearing Restoration Drug Candidate, FX-322

WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced this week the completion of enrollment in the single dose safety trial to evaluate FX-322, the company’s leading drug candidate for hearing restoration.  The randomized, double-blind, placebo-controlled trial will be assessing the safety of a single dose of FX-322 given by intratympanic administration in adult patients with…

Read More
decibel therapeutics hearing loss drug license oricula

Decibel Therapeutics Obtains Exclusive License to Develop and Commercialize ORC-13661 from Oricula Therapeutics

BOSTON & SEATTLE — Boston-based biotech firm, Decibel Therapeutics, announced this week that it has obtained “an exclusive, worldwide license to the development and commercialization of ORC-13661” from Oricula Therapeutics for the prevention of hearing loss and balance disorders due to the use of aminoglycoside antibiotics. As part of the agreement with Decibel, Oricula will…

Read More
auris medical hearing loss treatment

Auris Medical Receives FDA Guidance for Investigative Drug to Treat Sudden Sensorineural Hearing Loss

ZUG, SWITZERLAND — Biopharmaceutical company Auris Medical Holdings announced today that it has received feedback from a Type C meeting with the U.S. Food and Drug Administration (FDA) related to the development plan and regulatory pathway for AM-111, the company’s investigational treatment for sudden sensorineural hearing loss. The meeting had been conducted at the request of…

Read More
sensorion

Sensorion to Begin Patient Enrollment for Safety Study of Vertigo Drug, Seliforant

MONTPELLIER, FRANCE — Biotech firm Sensorion announced the initiation of patient enrollment in a Phase 2a study (SENS-111-202) to confirm the absence of certain side effects commonly experienced with meclizine (specifically, anticholinergic side effects like sedation and memory loss) during an evoked vestibular imbalance. SENS-111-202 is a randomized, double-blind, double-dummy, placebo-controlled, cross-over trial in patients designed…

Read More